Refine by
Risk Assessment Articles & Analysis
79 news found
l Glycosylation Analysis (Optional): Comparing antibody binding to glycosylated versus deglycosylated forms of the antigen to assess epitope accessibility. l Overlapping Peptide Library Design: Synthesizing a series of overlapping peptides based on the antigen sequence to identify linear epitopes. ...
They include efficacy tests, microbial contamination reports and full-service toxicological risk assessment. CD Formulation aids brands in protecting their reputation and fortifying consumer trust. ...
CD Formulation’s experienced analysis experts can perform tablet fragility tests by pharmacopeia methods, helping clients to conduct an appropriate risk assessment of the finished drug. Dissolution Test Drug dissolution test is a standardized method for measuring the release rate of a drug from a given dosage form, which helps to evaluate the performance of ...
BioMark’s blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe’s screen-eligible population who are most likely to benefit from a CT scan. ...
Elucid has developed FDA-cleared Plaque Analysis and investigational FFRCT tools designed to enable physicians to diagnose and understand the direct cause of myocardial ischemia, while also identifying coronary plaque that is at highest risk to rupture and result in a heart attack. “Elucid has developed a plaque analysis software based on ground truth histology which is ...
ByElucid
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article 20 ...
Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. ...
ByElucid
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
Last month the company announced that miR Sentinel™ Prostate Cancer Test is commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the risk of ...
These are all reasons why surface cleaning, disinfection, air quality, and careful personal and occupational hygiene are so critical for high risk environments such as hospitals, daycare centers, nursing homes, and other locations where people with undeveloped, suppressed, or weakened immune systems can be found.” With offices in New York and Florida, CTSI’s ...
With both expertise and advanced equipment, CD Formulation’s API-excipient compatibility analysis service can help assess the risk of API-excipient interactions before formulation development, thus saving both time and cost for clients. ...
Skrinings.lv also offers a breast cancer risk assessment tool in Russian, English and Latvian that has helped more than 8000 people take more control over their breast health and prevent devastating late-stage diagnoses. ...
” About DCISionRT for Breast DCIS DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. ...
The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...
Further, the totality of the safety and efficacy data for all three patients dosed to date gives us high confidence in our benefit-risk assessment of VX-880 and its potentially transformative profile,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. ...
“The DCISionRT test is an important risk assessment tool to determine which patients can safely omit RT, which patients will benefit greatly from RT, and which patients may need more aggressive treatment than ...
” About DCISionRT for Breast DCIS DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. ...
On-site booth will host interactive experiences including product trials, hands-on demonstrations, and education Today, Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, has acquired CUPTIMIZE™ Hip-Spine Analysis, giving surgeons an easy-to-use tool to better understand and address the impact of abnormal motion between the ...
About DCISionRT for Breast DCIS DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological Association. The study, led by Dr. Eric Klein, Emeritus Professor and Chair of the Glickman Urological ...